Biopharmaceutical Contract Manufacturing Study Finds Industry Growth Over the Past Two Years and Expects to Continue Its Growth Trajectory

SAN JOSE, Calif.--(Business Wire)--
The demand for biopharmaceutical contract manufacturing services is expected to
grow at 16% annually over the next 5 years as biopharmaceutical business models
shift toward more outsourcing of production requirements, as well as some large
pharmaceutical companies choosing not to expand their internal capacities.
Industry expression yields have improved significantly, and new technologies
such as better expression systems, more efficient cell lines and improved media
present new opportunities to improve productivity further.

The ninth industry study published by HighTech Business Decisions
"Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New
Capacities and Improved Performance" reports that current contractor capacity
utilization is slightly lower than 2006 levels. This temporary decline in
utilization results from a combination of previous investment in capacity,
improved expression yields, and slow down in biotechnology investments because
of the current financial markets. Over the next few years, demand is expected to
grow as new biopharmaceuticals move through the clinical pipeline and become
commercial products.

William Downey, president of HighTech Business Decisions, explains, "We
extensively interviewed 48 biomanufacturing and outsourcing directors of
biopharmaceutical and biotechnology companies worldwide, and 29
biopharmaceutical contract manufacturers ("CMOs"). There is general consensus
that the CMO industry as a whole will remain strong and grow, but the industry
will undergo consolidations."

The market for biopharmaceutical contract manufacturing is estimated to be
US$2.6B in 2009, and long-term growth prospects remain strong through 2014. This
900-page report with 290 summary data tables and charts provide in-depth
analysis of the dynamic factors impacting the industry, including new equipment
and disposable technologies, improved expression levels, increasing
competitiveness, changing outsourcing strategies, capacity forecasts, changes in
outsourcing spending and margins, and biomanufacturing in low-cost regions.

About HighTech Business Decisions

HighTech Business Decisions is a market research and consulting firm
specializing in the areas of pharmaceutical drug discovery and biopharmaceutical
contract manufacturing. The company has been producing in-depth public reports
and customized benchmarking, market analysis and customer loyalty programs for
over ten years. Visit us at www.HighTechDecisions.com

HighTech Business Decisions
William Downey, 408-978-1035
wdowney@hightechdecisions.com

Copyright Business Wire 2009